ProMIS Neurosciences, Inc.
1920 Yonge Street
Suite 200
Toronto, ON M4S 3E2
Canada
416 847 6898
https://www.promisneurosciences.com
版塊: Healthcare
行業: Biotechnology
全職員工: 6
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Eugene Williams | Co-Founder & Chairman | 256.81k | 無 | 1959 |
| Mr. Neil K. Warma M.B.A. | President, Interim CEO, Principal Executive Officer & Director | 37.35k | 無 | 1963 |
| Dr. Neil R. Cashman M.D. | Co-Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director | 335.87k | 無 | 1952 |
| Mr. Gavin T. Malenfant | Chief Operating Officer | 389.18k | 無 | 1964 |
| Mr. Daniel E. Geffken M.B.A. | Chief Financial Officer | 83.36k | 無 | 1957 |
| Dr. Johanne Kaplan Ph.D. | Chief Development Officer | 243.69k | 無 | 1960 |
| Dr. Ernest D. Bush Ph.D. | Head of Pharmacology/Toxicology & Senior Consultant | 無 | 無 | 無 |
| Dr. David Wishart Ph.D. | Chief Physics Officer | 無 | 無 | 無 |
| Mr. Dennis Chen Ph.D. | Head of Manufacturing & Senior Consultant | 無 | 無 | 無 |
| Dr. Larry Douglas Altstiel M.D., Ph.D. | Chief Medical Officer | 無 | 無 | 1950 |
描述
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
公司管治
截至 無 止，ProMIS Neurosciences, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
